Comparative Pharmacology
Head-to-head clinical analysis: GENTACIDIN versus NEOMYCIN POLYMYXIN B SULFATES BACITRACIN ZINC HYDROCORTISONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENTACIDIN versus NEOMYCIN POLYMYXIN B SULFATES BACITRACIN ZINC HYDROCORTISONE.
GENTACIDIN vs NEOMYCIN & POLYMYXIN B SULFATES & BACITRACIN ZINC & HYDROCORTISONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis.
Neomycin, polymyxin B, and bacitracin are antibiotics that inhibit bacterial protein synthesis, disrupt cell membrane integrity, and interfere with cell wall synthesis, respectively. Hydrocortisone is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
5-7 mg/kg IV every 24 hours.
Apply to affected area 3-4 times daily. Not for use in eyes.
None Documented
None Documented
2-3 hours in adults with normal renal function; extended to 24-48 hours in anuria or severe renal impairment, requiring dose adjustment.
Neomycin: 2-3h (normal renal); polymyxin B: 4-6h (normal renal), prolonged to 2-3 days in renal impairment; bacitracin: ~1.5h after IM; hydrocortisone: 1.5-2h (plasma). Topical: systemic levels negligible.
Renal: 95-98% unchanged via glomerular filtration; biliary/fecal: <2%.
Neomycin: >90% renal (unchanged) after parenteral; polymyxin B: ~60% renal (unchanged) over 72h; bacitracin: >90% renal (unchanged) after IM; hydrocortisone: hepatic metabolism, metabolites renally eliminated (<1% unchanged). Topical: negligible systemic absorption across intact skin (except bacitracin may be minimally absorbed).
Category C
Category A/B
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic